[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=99f97d61ab26f8049eb3793f31d9dc97638b590670307dcf83ecd1b16f885de8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752597060,
      "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "id": 135975206,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=99f97d61ab26f8049eb3793f31d9dc97638b590670307dcf83ecd1b16f885de8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Strengthens Pays $700M to Strengthen Oncology Portfolio with ISB 2001",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the confirmation of an exclusive licensing deal with IGI Therapeutics. The agreement is for lead asset ISB 2001, which targets oncology and autoimmune diseases. Under the terms of the agreement, AbbVie has secured rights to […]",
    "url": "https://finnhub.io/api/news?id=e9cfa875854575a24213105240b39ab02bdc1adba61c139388bc98857e3e20fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752585029,
      "headline": "AbbVie (ABBV) Strengthens Pays $700M to Strengthen Oncology Portfolio with ISB 2001",
      "id": 135965021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the confirmation of an exclusive licensing deal with IGI Therapeutics. The agreement is for lead asset ISB 2001, which targets oncology and autoimmune diseases. Under the terms of the agreement, AbbVie has secured rights to […]",
      "url": "https://finnhub.io/api/news?id=e9cfa875854575a24213105240b39ab02bdc1adba61c139388bc98857e3e20fd"
    }
  },
  {
    "ts": null,
    "headline": "Here's How to Play AbbVie Stock as it Reaches Golden Cross",
    "summary": "ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.",
    "url": "https://finnhub.io/api/news?id=f28b77868975c7f132bae34484b78583d0475940bc899f3b8a32f85e5e957415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752582900,
      "headline": "Here's How to Play AbbVie Stock as it Reaches Golden Cross",
      "id": 135962658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.",
      "url": "https://finnhub.io/api/news?id=f28b77868975c7f132bae34484b78583d0475940bc899f3b8a32f85e5e957415"
    }
  },
  {
    "ts": null,
    "headline": "Tax Court Breaks New Ground On The Deductibility Of Termination Fees With AbbVie Ruling",
    "summary": "On June 17, 2025, the Tax Court opinion in AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue was issued,1 holding that the approximately $1.6 billion termination fee AbbVie paid to its...",
    "url": "https://finnhub.io/api/news?id=8a965b6889aa61bb7c5312c54aba44a0712380fd80b17320818023fedfbedaa9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752574451,
      "headline": "Tax Court Breaks New Ground On The Deductibility Of Termination Fees With AbbVie Ruling",
      "id": 135945570,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "On June 17, 2025, the Tax Court opinion in AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue was issued,1 holding that the approximately $1.6 billion termination fee AbbVie paid to its...",
      "url": "https://finnhub.io/api/news?id=8a965b6889aa61bb7c5312c54aba44a0712380fd80b17320818023fedfbedaa9"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner Global Equity Q2 2025 Report",
    "summary": "The Global Equity composite rose 10.3% gross of fees in the second quarter, lagging the 11.7% gain in the MSCI ACWI Index.",
    "url": "https://finnhub.io/api/news?id=8ec65fb5791a8926881b2ee37698c3f7289d7fd8997db8809c0e93fef327274b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752573600,
      "headline": "Harding Loevner Global Equity Q2 2025 Report",
      "id": 135945766,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2067714497/image_2067714497.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Global Equity composite rose 10.3% gross of fees in the second quarter, lagging the 11.7% gain in the MSCI ACWI Index.",
      "url": "https://finnhub.io/api/news?id=8ec65fb5791a8926881b2ee37698c3f7289d7fd8997db8809c0e93fef327274b"
    }
  }
]